PSY42 Cost-Effectiveness of Plerixafor (PXF) for Stem Cell Mobilization in Lymphoma (NHL/HL) and Multiple Myeloma (MM) Patients in Poland  by Kaczor, M.P. et al.
A384  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
cost of blood production accounted only for the resources expended for collection, 
processing, laboratory testing, storage, as well as the indirect donor’s productivity 
loss. Hence, the cost associated to donor recruitment, pre-transfusion preparation, 
transfusion administration, follow up management of adverse events, and other 
long-term relevant costs were not taken into consideration. Two separate question-
naires were used to collect data regarding: personnel time, annual blood quantities 
collected, percentage of wastage, consumables utilization, institutional overheads, 
information technology expenditure, medical equipment utilized, nuclear acid tests, 
other laboratory tests and indirect costs. Data gather by 53 hospitals across the 
country. An economic model was build using also economic data collected by the 
National School of Public Health and the Ministry of Health. All data referred to the 
year 2012. Results: The cost distribution was positively skewed (skewness:1.530). 
The unweighted mean cost of collecting a blood unit was estimated at € 146.43 
(standard deviation: +€ 28.18, min/max: € 110.25-€ 240.84). In addition, the indirect cost 
of donors’ loss of productivity was estimated at € 33,70 (+€ 49,23). Major cost compo-
nent appears to be the cost of personnel, which was estimated at € 46.86 (+€ 24.86, 
€ 16.49-€ 132.59), accounting for 32.0% of the total direct cost. The average of blood 
unit wastage was estimated at 4.90%. There were not differences between the cost 
of producing a unit of blood in Athens compared with the rest of the country (Man-
Whitney test, p-value: 0.341). ConClusions: This study indicates that the cost of 
producing a cost of blood isn’t insignificant. These figures need to be complemented 
with those concerning the cost of transfusion to have a full picture of producing 
and using a cost of blood locally.
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objeCtives: The significance of cystic fibrosis associated with early disability, 
the need for long-term regular treatment and follow-up and is associated with 
high costs. Data reflecting the socio-economic burden of cystic fibrosis in Russia is 
low, which dictates the need for clinical and economic studies, for example – this 
study. Methods: An assessment of the burden of cystic fibrosis with the use of 
tobramycin inhalation solution from different manufacturers and powder inhaled 
tobramycin (Tobi Podhaler) for the treatment of Pseudomonas infections in patients 
with cystic fibrosis. The study took into account only the direct medical costs of one 
patient based on standards of outpatient and inpatient care for patients with cystic 
fibrosis. Results: The burden of cystic fibrosis with the use of tobramycin powder 
for inhalation Tobi Podhaler with the time horizon of 10 years is reduced faster 
than in similar groups of patients: the point of profitability is on the eighth year of 
treatment when compared with tobramycin-Gobbi and a 9-year - with Bramitobom, 
when the use of Tobi Podhaler requires less cost to 46,372 USD and 50,138, respec-
tively. ConClusions: Additional costs are difficult to calculate due to the fact that 
tobramycin solution for inhalation requires compliance with ‘‘cold chain’’ at all 
stages of the life cycle of the product: transportation, storage at the distributor and 
at the pharmacy, storage at home. Thus, obtained data in controlled efficacy studies 
of tobramycin solution in actual practice, may be significantly lower.
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objeCtives: To evaluate the cost-effectiveness of prolonged release oxycodone/
naloxone combination tablets [OXN; naloxone is added to counteract opioid-induced 
constipation (OIC)] in patients who are constipated despite the use of two laxatives, 
compared with prolonged release oxycodone (OXY) alone. Methods: A model used 
data from one phase II randomised, controlled trial (RCT) in patients with moder-
ate/severe cancer pain and a pooled analysis of two phase III RCT’s in patients with 
moderate/severe non-cancer pain. A subgroup of patients with OIC who had failed on 
two or more laxatives at screening was applied in the analysis (n= 178). The drug cost 
for pain therapy was combined with laxative costs and other resources to calculate 
the cost difference between OXN and OXY. Quality-adjusted life-year (QALY) gains 
were calculated by mapping Bowel Function Index scores to EQ-5D utility values. 
Deterministic sensitivity analyses were performed. The analysis was conducted from 
the perspective of the UK National Health Service (NHS). Results: The incremental 
cost of OXN vs. OXY was £409.60 for the average treatment duration of 301 days. OXN 
gave an incremental QALY gain of 0.0524. The estimated incremental cost-effective-
ness ratio (ICER) was £7,821.80 for OXN vs. OXY. The ICER remained below £30,000 for 
all sensitivity analyses, with OXN dominating OXY in some scenarios when higher 
constipation unit costs were applied. ConClusions: Patients treated with OXN 
experienced a quality of life gain, and OXN had an ICER considerably below thresholds 
normally regarded as cost-effective in the UK (£20,000 – 30,000/QALY). More research 
is required into the cost of treating OIC, with OXN dominating OXY (total cost saving 
to the NHS and quality of life benefit) in sensitivity on OIC unit costs. OXN is therefore 
estimated to be a cost-effective option for treating patients with moderate to severe 
pain and OIC, who are constipated despite the use of two laxatives.
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Drug costs were based on the 10-μ g per hour buprenorphine patch and the equiv-
alent tramadol dose (2013 British National Formulary listings). Fracture costs 
were from a recent National Institute of Health and Care Excellence submission; 
utility weights were obtained from the literature. Results: For a population of 
100,000, the model predicted a reduction in the number of additional fractures 
(forearm, hip, or spine) associated with analgesic use from over 2,000 for patients 
treated with tramadol to under 20 for patients treated with buprenorphine. An 
estimated £5.5 million was saved and over 1,300 QALYs were gained. In sensitiv-
ity analysis, buprenorphine was dominant in most analyses and most sensitive 
to treatment duration. The cost-effectiveness estimate was below £20,000 per 
QALY in all scenarios. ConClusions: Our preliminary analysis suggests that 
buprenorphine has the potential to be dominant and cost-effective, compared 
with tramadol.
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objeCtives: Infantile Pompe disease is a rare metabolic disease. Enzyme replace-
ment therapy (ERT) has proven to have substantial effects on survival in infantile 
Pompe disease. However, costs of therapy are very high. This paper assesses the 
cost-effectiveness of ERT in infantile Pompe disease. Methods: A patient simula-
tion model was used to compare costs and effects of ERT with costs and effects 
of supportive therapy (ST). The model was filled with data on survival, quality of 
life and costs. For both arms of the model, data on survival were obtained from 
international literature. In addition, survival as observed among 20 infantile Dutch 
patients, who all received ERT, was used. Quality of life was assumed to be the 
same in both groups and was measured using the EQ-5D. Costs included the costs 
of ERT, which depend on a child’s weight, and costs of health care use, informal 
care and infusions. A lifetime time horizon was used, with semi-annual time 
cycles. Results: On average, ST receiving patients were modelled not to survive 
the first half year of life; whereas the life expectancy in the ERT patients was 
modelled to be almost 14 years. Lifetime incremental QALYs were 6.7. Incremental 
costs were estimated to be € 7.0 million, consisting for 95% of treatment costs. 
The incremental costs per QALY were estimated to be € 1.0 million. The incremen-
tal cost per life year gained was estimated to be € 0.5 million. ConClusions: In 
2012, the Dutch health care insurance board advised the Minister of Health to 
reimburse enzyme replacement therapy in Pompe disease, despite its unfavorable 
ICER. Other factors, such as the rarity of the disease, equity considerations, and 
the relatively modest budget impact have probably played a role in this decision. 
These and other factors could be incorporated in a formal multi-criteria decision 
analyses.
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objeCtives: To estimate the incremental cost-effectiveness (ICER) and cost-util-
ity ratio (ICUR) of belimumab compared to standard care (SC) for the treatment 
of patients with Systemic Lupus Erythematosus (SLE) in Portugal. Methods: A 
lifetime microsimulation model represented the complex and multidimensional 
course of SLE, based on long term data from a US cohort of SLE patients. The 
analysis was undertaken using a societal perspective with 5% discount rates 
for costs (direct and indirect costs), and effects [Life Years Gained (LYG) and 
QALY (Quality Adjusted Life Years)]. The model was calibrated with the phase 
III BLISS trials data, and UK utility values. The ICER and ICUR were estimated 
by comparison of SC vsSC with belimumab, with a lifetime analytic horizon. 
Belimumab non-responders were discontinued after 6 months and belimumab 
treatment was maximized at 3 years. Results: The model demonstrated that 
adding belimumab to SC to treat SLE patients with high disease activity, positive 
anti-dsDNA antibodies, and low complement (C3, C4) levels, would result in a 
potential gain of 0.41 life-years, and 0.32 QALYs. Incremental costs were€ 8,400, 
resulting in an ICER of € 20,649/LYG and ICUR of € 25,917/QALY for the base case 
scenario. ICER and ICUR are insensitive to the follow-up treatment costs of SLE, 
and wastage of drug; moderately sensitive to duration of treatment, and waning 
time; and very sensitive to discount rates, and exclusion of indirect costs. The 
probabilistic sensitivity analysis reveals a cost-effectiveness probability of 59% 
for a € 30,000/QALY threshold, and a median ICUR of € 27,932/QALY (95% confi-
dence interval: € 14,215/QALY - € 52,279/QALY). ConClusions: The analysis sug-
gests that adding belimumab to SC for SLE patients with high disease activity, 
positive anti-dsDNA, and low complement levels, is cost-effective, presenting 
an ICER and ICUR below the commonly used threshold. This study is funded by 
GlaxoSmithKline, protocol #HO-13-13626
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objeCtives: To estimate the cost of producing a unit of blood from a NHS and 
societal perspective in Greece. Methods: In line with the official guidelines, the 
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objeCtives: Phenylketonuria (PKU) is an orphan disease with incidence rate 1:5000 
in Egypt. Cost-effectiveness of Sapropterin versus Phenylalanine (PHE) free diet in 
PKU patients from the insurer perspective was evaluated over a time horizon of 10 
years. Methods: A cohort Markov chain model with six health states: healthy, mild 
PKU, controlled mild PKU, classical PKU, controlled classical PKU and death was 
identified based on the process of the disease. The length of a cycle was set at one 
year. The transition probabilities were derived from updated, previously published 
studies in Egyptian patients with PKU. Relative risk of Sapropterin and utilities were 
derived using international published sources. Direct Medical costs were obtained 
from the Ministry of Health mandatory Tarrif in Egypt. All costs and effects were 
discounted at 3.5% annually. All costs were reported in Egyptian pounds of the 
financial year 2013. Deterministic sensitivity analysis was conducted. Results: 
Total costs for Sapropterin and PHE free diet were 304.1687 EGP and 188.6498 EGP 
respectively. QALYs for Sapropterin and PHE free diet were 0.00566 and 0.00547 
respectively. The incremental cost-effectiveness ratio (ICER) for Sapropterin versus 
PHE free diet was 602,933 EGP/QALY. Sapropterin is not cost effective because it is 
more than 3 times GDP/capita in Egypt (57,566 EGP). The ICER was most sensitive to 
the utility of the states ‘classical PKU’ and ‘controlled classical PKU’. ConClusions: 
World Health Organization recommends that interventions that cost more than 3 
times GDP/capita for one Disability Adjusted Life Year (DALY) avoided should not be 
reimbursed. Despite the difference between DALY and QALY, one can assume they 
are similar to be able to put a value on the outcome. Sapropterin doesn’t represent 
a good value for money compared to PHE free diet in the Egyptian PKU patients.
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objeCtives: LighterLife Total (LLT) is a weight loss programme for the obese (BMI 
≥ 30kg/m2) combining a very low calorie diet (VLCD) with weekly support groups 
for behaviour modification. This study evaluated the cost-effectiveness of LLT com-
pared with dietary and surgical interventions. This is the first study assessing the 
cost-effectiveness of a VLCD. Methods: A cohort model was developed to assess 
the reduction in BMI in the first 12 months following intervention with LLT, gastric 
banding, gastric bypass, Weight Watchers, Counterweight, Slimming World and no 
treatment, and the subsequent yearly BMI increase. Published all cause-mortality was 
applied by age and BMI. Co-morbidity prevalence (diabetes, colorectal cancer, CHD) 
was applied by BMI. Costs were applied for each intervention and for co-morbidities, 
from a UK health care perspective. Utilities were calculated by BMI with an additional 
decrement for co-morbidities. A 10 year time horizon was used. Analyses were run for 
two subgroups: BMI 30-40 in and BMI > 40. Results: BMI 30-40: compared against no 
treatment, Counterweight, Weight Watchers and Slimming World, LLT was associated 
with higher costs, but also greater QALYs and was cost-effective against all, with incre-
mental cost-effectiveness ratios of £14,937, £16,004, £16,182, and £19,840, respectively. 
BMI > 40: compared against no treatment LLT incurred higher costs, but also greater 
QALYs and was cost-effective (ICER = £5,349). LLT was less effective than banding and 
bypass. The budget impact of uptake of LLT across the UK was assessed for both BMI 
30-40 and BMI > 40 groups. ConClusions: BMI 30-40: LLT was more costly than 
dietary interventions, but lead to increased QALYs and was estimated to be cost-effec-
tive. BMI > 40: LLT resulted in a lower initial BMI reduction than gastric banding and 
bypass. LLT was estimated to be cost-effective against no treatment in both groups.
PSY47
full CoSt of PlaSma from VoluntarY non remunerated donorS in 
italY
Zaniolo O.1, Povero M.1, Gandini G.2, Aprili G.2, Eandi M.3
1AdRes HE&OR, Turin, Italy, 2University of Verona, VERONA, Italy, 3University of Torino, Torino, 
Italy
objeCtives: In Italy, within the legal mandate to pursue national self-sufficiency 
of secondary blood products, the Regions are starting to organize trade to off-
set need/availability unbalances. Therefore the determination of the full cost to 
the Regions of plasma collection and handling is needed. Methods: Plasma 
is obtained from voluntary, non-remunerated donors either from full blood or 
from apheresis, and is collected either directly in facilities of the Regional Health 
Services, or indirectly through the net of donors’ associations before being deliv-
ered to the transformation industry for processing. Amount and costs of materi-
als and activities needed for collecting, producing, validating, and distributing 
plasma were obtained from the transfusional medicine department of the Verona 
province, Veneto Region. Attributable overhead expenses are assumed at 15% of 
direct cost. When plasma is collected as part of the whole blood or from multi-
component apheresis, common costs are attributed basing on the commercial 
value of single components, taken as proxy of the willingness-to-pay for them. 
In an alternative scenario, only product-specific costs are attributed to plasma 
recovered from whole blood donations, for which the driving need is the supply 
of red blood cells. Results: Total cost per liter of plasma sent for processing 
is estimated in 114 and 286 euros, respectively, for collection from whole blood 
and apheresis. Given the current mix of plasma origin, the weighed mean cost 
of plasma to the Regions before processing charges is estimated in 157 € . When 
plasma recovered from whole blood donations is considered by-product, its cost 
per liter sent to industry is estimated in 27 € , and the corresponding weighed 
mean cost in 92 € . ConClusions: The Italian donor-based system, in addition to 
objeCtives: To assess cost-effectiveness of PXF, used in combination with G-CSF 
versus standard mobilization options used alone, to enhance mobilization of haema-
topoietic stem cells to the peripheral blood for collection and subsequent autologous 
transplantation (auto-HCT). Target population, as defined by Polish opinion leaders, 
are patients with NHL/HL or MM whose cells mobilize poorly, i.e. predicted poor 
mobilizers (peripheral blood CD34+ cell count < 10/mL) and proven poor mobilizers 
(failure of previous mobilizations). Methods: PXF is an add-on therapy to currently 
reimbursed standard mobilization (SM) options: G-CSF or chemotherapy plus G-CSF. 
Two scenarios were compared: with and without PXF. Analysis was performed using 
a Markov decision model, developed in TreeAge Pro 2013. A probabilistic (Monte Carlo 
simulation) model with time-dependent transition probabilities included initial 
cycle, during which the individual undergoes mobilization and auto-HCT if cell 
collection is successful, and four mutually exclusive health states: progression-free 
survival (remission and durable remission – lymphomas only), further treatment 
after progression, palliative treatment/observation and death. A one-year Markov 
cycle length was used with half-cycle correction. Baseline cohort characteristics, 
disease progression and utility estimates were obtained from systematic literature 
review and questionnaire study among Polish clinical practitioners. The analysis 
was conducted from the Polish public payer, patients, and societal perspective, over 
a lifetime horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: 
The mean QALY gain were 7,378 (PXF) and 6,452 (SM). The mean costs were 188,404 
PLN (€ 45,019) (PXF) and 157,073 PLN (€ 37,532) (SM). Base-case incremental cost-util-
ity ratio (ICUR) in NHL/HL/MM population was 33,821 PLN/QALY (€ 8,082). Probability 
of PXF being cost-effective in Poland when compared to SM is 99,8% (current thresh-
old of 105,801 PLN/QALY (€ 25,281)). ConClusions: Based on accepted cost/QALY 
threshold values in the Polish settings, PXF was proved to be cost-effective option 
for NHL/HL/MM patients with poor response to SM regimens.
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objeCtives: To estimate the cost-utility of BEL treatment of patients with SLE as an 
add-on therapy to intensive standard of care (SOC) vs. SOC in Poland. Methods: 
The general population considered in the analysis were patients with SLE with sig-
nificant disease activity, who met criteria of SLE diagnosis and were ineffectively 
treated with SOC. CUA was performed from the public payer perspective. The lifetime 
horizon was assumed. The decision model was developed in MS Excel and adjusted to 
Polish conditions. The calculations were performed using Monte Carlo microsimula-
tion. The model included data from international clinical studies and Polish data on 
costs and resource utilization. Direct medical costs were included: costs of drugs, 
administration, diagnostic, monitoring and costs related to disease activity. Results were 
calculated for two patients populations: target population 1 (TP1) - patients with 
positive anti-dsDNA, low complement and ≥ 10 scores in SELENA-SLEDAI scale and 
target population 2 (TP2) - patients with positive anti-dsDNA, low complement, ≥ 6 
scores in SELENA-SLEDAI scale and necessity of corticosteroids use. Results: CUA 
results showed that BEL compared to SOC is more costly however, also more effective 
therapy. The ICUR was 113,986 PLN/QALY and 108,744 PLN/QALY, respectively for TP1 
and TP2. Obtained results are placed slightly above the Polish acceptability threshold. 
Additional health effects related to BEL treatment instead of SOC were noticed both 
in LYG and QALY (0.432 and 0.4 LYG; 0.322 and 0.294 QALY, respectively for TP1 and 
TP2). Moreover, the model suggests lower frequency of cardiovascular events, and also 
pulmonary and renal complications in BEL arm. ConClusions: Since there is cur-
rently no effective treatment option of SLE in Poland, reimbursement of belimumab 
will give patients an access to a safe and effective therapy, which allows them to 
return to active life and career and also to improve their quality of life.
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objeCtives: To estimate the cost-utility of deferasirox (DSX) treatment of iron over-
load due to frequent blood transfusions in children and adolescents in Polish condi-
tions. Methods: Clinical effectiveness data were taken from previously performed 
systematic review of deferasirox for the treatment of pediatric patients (age ≤ 18 
years) with iron overload due to frequent blood transfusions. The way of administra-
tion of chelation therapy (parenteral vs. oral) significantly affects patients’ function-
ality and quality of life. Therefore it was decided to perform a cost-utility analysis. 
Analogous to other economic studies, it was assumed that patient survival was the 
same for both compared interventions: deferasirox and deferoxamine (DFO). In the 
analysis a simple decision model was developed. The calculations were performed 
using Monte Carlo microsimulation technique (100,000 trials). Only direct medical 
costs were included in the analysis: costs of drugs and their administration, costs 
of monitoring and costs of blood transfusions. The time horizon of the analysis was 
one-year period. Two perspectives were considered: a public payer (National Health 
Fund, NHF) and the patient and NHF perspective. The measure of effects was QALY 
(quality adjusted life years). Results: The results showed that DSX compared to 
current standard treatment of iron overload due to frequent blood transfusions 
(DFO) in the children and adolescents is more costly however also more effective 
therapy from both considered perspectives. The ICUR (incremental cost-utility ratio) 
of replacing DFO by DSX was 26,180 PN/QALY from NHF perspective. The results from 
both patient and NHF perspective was similar. ConClusions: With reference to 
the acceptability threshold in Poland the oral chelation therapy in the population 
of children and adolescents with iron overload due to frequent blood transfusions 
with deferasirox is cost effective intervention when compared with deferoxamine.
